This site is intended for Healthcare Professionals outside the US

JAKAVI is a potent JAK1 and JAK2 inhibitor

JAKAVI acts on both JAK1 and JAK2 to inhibit overactive JAK/STAT signalling in myelofibrosis1-3

  • JAKAVI binds to the kinase domain of JAK1 and JAK2 and inhibits JAK1 and JAK2 signalling regardless of the JAK2V617F mutation status1-3
  • JAKAVI inhibits JAK stimulation of STAT and downstream effects on cellular proliferation3

Next: COMFORT-I study design

JAK=Janus kinase; MOA=mechanism of action; STAT=signal transducers and activators of transcription protein.

References:

  1. Verstovsek S, Almomen AK, Newberry KJ, Aleem A. Development of ruxolitinib as a myelofibrosis therapy. J Appl Hematol. 2013;4(3):89-95.
  2. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
  3. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; May 2017.